Seeking Alpha

Regeneron (REGN +9.4%) pops on a blowout Q1, posting a surprise profit on a revenue number that...

Regeneron (REGN +9.4%) pops on a blowout Q1, posting a surprise profit on a revenue number that was easily 30% above consensus estimates. Total revenue doubled on record sales of Eyelea that came in at nearly twice consensus estimates. The company adds that the outperformance is likely to continue, and doubles its 2012 revenue expectations for the drug. Baird says the results were “bigger than our wildest expectations.”

Check out Seeking Alpha’s new Earnings Center »

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs